Publication | Closed Access

Phase I/II Study of Azacitidine (AZA) with Venetoclax (VEN) and Magrolimab (Magro) in Patients (pts) with Newly Diagnosed (ND) Older/Unfit or High-Risk Acute Myeloid Leukemia (AML) and Relapsed/Refractory (R/R) AML

Hematological MalignancyOncologyPhase I/ii StudyMixed-phenotype Acute LeukemiaPharmacotherapyMedicineRadiation OncologyCancer ResearchMyeloid Neoplasia